ZIVO Bioscience, Inc. (ZIVOW)

ZIVO Bioscience, Inc. (ZIVOW) — VMCI valuation read

Composite valuation read on ZIVOW: VMCI 40/100 against a Healthcare sector median of 50. The 10-point below-median print is the headline number for ZIVO Bioscience, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for ZIVOW: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on ZIVOW: ZIVOW trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -1.1x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

ZIVOW fell 2.5% over the trailing 7 days, with a -2.2% read on a 30-day basis.